What is he best known for?
The fields of study he is best known for:
- Cancer
- Immune system
- Internal medicine
His primary areas of study are Immunology, Immune system, Cancer research, Tumor-infiltrating lymphocytes and CD8.
His Immunology study combines topics from a wide range of disciplines, such as Cytotoxic T cell and Cancer.
The Cancer research study combines topics in areas such as Sunitinib, Fas ligand, Myeloid-derived Suppressor Cell and Pathology.
In his study, which falls under the umbrella issue of Sunitinib, Kidney cancer is strongly linked to Tyrosine-kinase inhibitor.
His Tumor-infiltrating lymphocytes study combines topics in areas such as Interleukin 2, Cytokine, Signal transduction, T-cell receptor and CD3.
His study explores the link between Tumor progression and topics such as FOXP3 that cross with problems in IL-2 receptor.
His most cited work include:
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients (689 citations)
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients (689 citations)
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (401 citations)
What are the main themes of his work throughout his whole career to date?
James H. Finke focuses on Immunology, Cancer research, Renal cell carcinoma, Immune system and Internal medicine.
As part of one scientific family, he deals mainly with the area of Immunology, narrowing it down to issues related to the Cytotoxic T cell, and often Cytotoxicity.
His Cancer research research includes themes of Peripheral blood mononuclear cell, CD8, Programmed cell death and Myeloid-derived Suppressor Cell.
His Myeloid-derived Suppressor Cell research focuses on Sunitinib and how it connects with Tyrosine-kinase inhibitor, FOXP3 and Kidney cancer.
His research integrates issues of Peripheral blood, Carcinoma, IL-2 receptor and Kidney in his study of Renal cell carcinoma.
James H. Finke has included themes like Tumor progression and Angiogenesis in his Immune system study.
He most often published in these fields:
- Immunology (46.06%)
- Cancer research (36.51%)
- Renal cell carcinoma (27.39%)
What were the highlights of his more recent work (between 2010-2020)?
- Myeloid-derived Suppressor Cell (15.35%)
- Immunology (46.06%)
- Cancer research (36.51%)
In recent papers he was focusing on the following fields of study:
James H. Finke mainly focuses on Myeloid-derived Suppressor Cell, Immunology, Cancer research, Immune system and Renal cell carcinoma.
James H. Finke has researched Myeloid-derived Suppressor Cell in several fields, including Tumor microenvironment, T cell, Peripheral blood mononuclear cell, Sunitinib and Cystectomy.
His Immunology research includes elements of Cancer, Tumor progression and Melanoma.
His research on Cancer research also deals with topics like
- Inflammatory biomarkers most often made with reference to Metastatic Urothelial Carcinoma,
- Signal transduction which intersects with area such as Molecular biology.
The concepts of his Immune system study are interwoven with issues in Immunosuppression and Kidney cancer.
His study in Renal cell carcinoma is interdisciplinary in nature, drawing from both Carcinoma and Nephrectomy.
Between 2010 and 2020, his most popular works were:
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma (224 citations)
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. (212 citations)
- Defining the critical hurdles in cancer immunotherapy (132 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Immune system
- Internal medicine
His primary areas of investigation include Myeloid-derived Suppressor Cell, Immunology, Cancer research, Sunitinib and Immune system.
His Myeloid-derived Suppressor Cell research is multidisciplinary, incorporating elements of Bone marrow and Pathology.
Much of his study explores Immunology relationship to Cancer.
His Cancer research study incorporates themes from Receptor, Autocrine signalling, Signal transduction and CD44.
The Sunitinib study combines topics in areas such as Tumor microenvironment and T cell.
The various areas that he examines in his Tumor microenvironment study include Sunitinib malate, Tyrosine-kinase inhibitor, Dendritic cell, Kidney cancer and Interleukin 2.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
